🍽️ mercaptopurine,(prescription)

AI Engines For more Details: PerplexityKagi LabsYou

  1. Antineoplastic Activity: Mercaptopurine is classified as an antimetabolite and immunosuppressive agent. It works by interfering with the synthesis of DNA and RNA in rapidly dividing cells, including cancer cells, thereby inhibiting their proliferation and inducing cell death. In the treatment of ALL, mercaptopurine is often used as part of combination chemotherapy regimens to achieve remission and prevent disease recurrence.

  2. Induction and Maintenance Therapy for ALL: Mercaptopurine is a key component of multi-agent chemotherapy protocols used in the induction and maintenance phases of treatment for ALL, particularly in pediatric patients. It helps eradicate leukemic cells from the bone marrow and peripheral blood, leading to remission and improving overall survival rates. Mercaptopurine may be used in combination with other chemotherapeutic agents such as methotrexate, vincristine, and corticosteroids.

  3. Immunosuppressive Effects: In addition to its anticancer properties, mercaptopurine exhibits immunosuppressive effects by inhibiting the proliferation of T and B lymphocytes and suppressing immune responses. This mechanism of action is utilized in the treatment of autoimmune disorders such as Crohn's disease and ulcerative colitis, where excessive immune activation contributes to inflammation and tissue damage in the gastrointestinal tract.

  4. Maintenance of Remission in Inflammatory Bowel Disease (IBD): Mercaptopurine is effective in maintaining remission and preventing disease flare-ups in patients with Crohn's disease and ulcerative colitis who have achieved clinical remission with initial therapy. By modulating immune function and reducing inflammation, mercaptopurine helps control symptoms, promote mucosal healing, and prolong periods of disease quiescence.

  5. Thiopurine Metabolism and Genetic Variability: Mercaptopurine is a prodrug that undergoes extensive metabolism in the body, primarily via the thiopurine S-methyltransferase (TPMT) pathway. Genetic variations in the TPMT gene can influence individual responses to mercaptopurine therapy, with deficient or absent TPMT activity associated with an increased risk of severe myelosuppression and other adverse effects. TPMT genotyping or phenotyping may be performed to guide dosing and reduce the risk of toxicity.

  6. Side Effects and Adverse Reactions: Common side effects of mercaptopurine therapy include bone marrow suppression (resulting in leukopenia, thrombocytopenia, and anemia), gastrointestinal disturbances (such as nausea, vomiting, and diarrhea), hepatotoxicity, pancreatitis, and increased susceptibility to infections. Patients receiving mercaptopurine require close monitoring of blood cell counts, liver function tests, and clinical symptoms to detect and manage potential complications.

  7. Drug Interactions: Mercaptopurine may interact with other medications, including allopurinol (which inhibits mercaptopurine metabolism), azathioprine (which has similar immunosuppressive properties), and drugs that affect hepatic metabolism or renal excretion. Concomitant use of mercaptopurine with other potentially myelosuppressive agents or hepatotoxic drugs should be carefully monitored to avoid additive adverse effects.

  8. Pregnancy and Fertility: Mercaptopurine is classified as a pregnancy category D medication due to its teratogenic effects and potential harm to the fetus. Women of childbearing age receiving mercaptopurine therapy should use effective contraception to prevent pregnancy during treatment. Additionally, mercaptopurine may impair fertility in both men and women, and counseling regarding reproductive risks and options should be provided to patients prior to initiating therapy.

;

Check for interactions on Supp.AI   |   πŸ“š PubMed Citations   |   βš—οΈ Compensation for antibiotic usage

Data Contradictions β€” Limits of Certainity

Impacted of mercaptopurine,(prescription) On Probiotics

Rank Probiotic Impact
species Akkermansia muciniphila Reduces
species Bifidobacterium adolescentis Reduces
species Bifidobacterium longum Reduces
subspecies Bifidobacterium longum subsp. infantis Reduces
subspecies Bifidobacterium longum subsp. longum Reduces

Bacteria Impacted by mercaptopurine,(prescription)

We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.

πŸ§™?

Taxonomy Rank Effect Citations Notation
Clostridioides genus Decreases 👪 Source Study
Segatella genus Decreases 👪 Source Study
Coprococcus genus Decreases 👪 Source Study
Collinsella genus Decreases 👪 Source Study proinflammatory
Blautia genus Decreases 👪 Source Study
Eggerthella genus Decreases 👪 Source Study
Agathobacter genus Decreases 👪 Source Study
Lacrimispora genus Decreases 👪 Source Study
Fusobacterium genus Decreases 👪 Source Study Periodontal disease, Lemierre syndrome, skin ulcers
Akkermansia genus Decreases 👪 Source Study
Thomasclavelia genus Decreases 👪 Source Study
Odoribacter genus Decreases 👪 Source Study
Bacteroides genus Decreases 👪 Source Study
Dorea genus Decreases 👪 Source Study
Mediterraneibacter genus Decreases 👪 Source Study
Bifidobacterium genus Decreases 👪 Source Study
Streptococcus genus Decreases 👪 Source Study
Parabacteroides genus Decreases 👪 Source Study BMI, fat percent,blood pressure
Roseburia genus Decreases 👪 Source Study
unclassified Fusobacterium no rank Decreases ⚗️ Source Study
unclassified Robinsoniella no rank Decreases ⚗️ Source Study
unclassified Negativicoccus no rank Decreases ⚗️ Source Study
Eggerthellales order Decreases ⚗️ Source Study
Clostridioides difficile species Decreases 📓 Source Study Colitis
Segatella copri species Decreases 📓 Source Study Over 70%ile Indicator of mycotoxin present
Coprococcus comes species Decreases 📓 Source Study
Collinsella aerofaciens species Decreases 📓 Source Study
Blautia obeum species Decreases 📓 Source Study
Eggerthella lenta species Decreases 📓 Source Study
Agathobacter rectalis species Decreases 📓 Source Study
Lacrimispora saccharolytica species Decreases 📓 Source Study
Fusobacterium nucleatum species Decreases 📓 Source Study Infectious bacteria
Akkermansia muciniphila species Decreases 📓 Source Study
Bacteroides thetaiotaomicron species Decreases 📓 Source Study
Thomasclavelia ramosa species Decreases 📓 Source Study
Bifidobacterium longum species Decreases 📓 Source Study
Odoribacter splanchnicus species Decreases 📓 Source Study
[Ruminococcus] torques species Decreases 📓 Source Study
Dorea formicigenerans species Decreases 📓 Source Study
Streptococcus parasanguinis species Decreases 📓 Source Study
Streptococcus salivarius species Decreases 📓 Source Study Infectious bacteria
[Ruminococcus] gnavus species Decreases 📓 Source Study
Anaerofustis stercorihominis species Decreases ⚗️ Source Study
Parvibacter caecicola species Decreases ⚗️ Source Study
Negativicoccus sp. S5-A15 species Decreases ⚗️ Source Study
Slackia sp. NATTS species Decreases ⚗️ Source Study
Bifidobacterium adolescentis species Decreases 📓 Source Study
Allisonella histaminiformans species Decreases ⚗️ Source Study
Pseudoflavonifractor capillosus species Decreases ⚗️ Source Study
[Collinsella] massiliensis species Decreases ⚗️ Source Study
Bacteroides fragilis species Decreases 📓 Source Study H02076 Bacteroides infection
Parabacteroides merdae species Decreases 📓 Source Study Infectious bacteria
Roseburia intestinalis species Decreases 📓 Source Study
Fusobacterium nucleatum subsp. nucleatum subspecies Decreases 👶 Source Study
Bifidobacterium longum subsp. infantis subspecies Decreases 👶 Source Study
Bifidobacterium longum subsp. longum subspecies Decreases 👶 Source Study
Bifidobacterium longum subsp. suillum subspecies Decreases 👶 Source Study
Chlamydiae/Verrucomicrobia group superphylum Decreases ⚗️ Source Study

Impact of mercaptopurine,(prescription) on Conditions from US National Library of Medicine

A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.

We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive   X|increases + Y|decrease = Negative.

Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.

Condition Positive Impact Negative Impact Benefit Ratio Impact
Acne 0.1 -0.1
ADHD 1.8 1 0.8
Age-Related Macular Degeneration and Glaucoma 0.2 0 0
Allergic Rhinitis (Hay Fever) 0.4 0.7 -0.75
Allergies 4.3 1.9 1.26
Allergy to milk products 0.2 0.2 0
Alopecia (Hair Loss) 1.1 1.1
Alzheimer's disease 2.6 3.1 -0.19
Amyotrophic lateral sclerosis (ALS) Motor Neuron 2.2 0.8 1.75
Ankylosing spondylitis 2.4 0.8 2
Anorexia Nervosa 0 1.1 0
Antiphospholipid syndrome (APS) 0.7 0.7
Asthma 1.1 1.4 -0.27
Atherosclerosis 1 0.9 0.11
Atrial fibrillation 2.1 1.3 0.62
Autism 7 5.3 0.32
Barrett esophagus cancer 0.4 0.1 3
Bipolar Disorder 0.2 1 -4
Brain Trauma 0.6 0.2 2
Carcinoma 2.3 1.7 0.35
Celiac Disease 0.5 2 -3
Cerebral Palsy 0.7 0.7 0
Chronic Fatigue Syndrome 2.2 3.8 -0.73
Chronic Kidney Disease 1.3 1.9 -0.46
Chronic Lyme 0.2 -0.2
Chronic Obstructive Pulmonary Disease (COPD) 1.1 0.5 1.2
Chronic Urticaria (Hives) 0.1 1.9 -18
Coagulation / Micro clot triggering bacteria 0.2 0.6 -2
Colorectal Cancer 2.1 1.1 0.91
Constipation 0.2 0.5 -1.5
Coronary artery disease 1.2 1 0.2
COVID-19 7.7 9.2 -0.19
Crohn's Disease 4.6 4 0.15
cystic fibrosis 0.3 -0.3
deep vein thrombosis 0.2 -0.2
Depression 4.5 7 -0.56
Dermatomyositis 0.1 0.1 0
Eczema 0.2 0.6 -2
Endometriosis 1.6 0.2 7
Eosinophilic Esophagitis 0.4 0.4
Epilepsy 2.3 2.1 0.1
Fibromyalgia 1.2 2.3 -0.92
Functional constipation / chronic idiopathic constipation 0.9 2.3 -1.56
gallstone disease (gsd) 0.7 0.6 0.17
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus 0.5 1.1 -1.2
Generalized anxiety disorder 1.1 1.2 -0.09
Glioblastoma 0.1 -0.1
Gout 0.5 -0.5
Graves' disease 0.8 1.2 -0.5
Halitosis 0.6 0.1 5
Hashimoto's thyroiditis 1.7 0.3 4.67
Hidradenitis Suppurativa 0.5 0.5
Histamine Issues,Mast Cell Issue, DAO Insufficiency 1.2 1.1 0.09
hypercholesterolemia (High Cholesterol) 0.2 0.8 -3
hyperglycemia 2 -2
Hyperlipidemia (High Blood Fats) 1 0.5 1
hypersomnia 0.5 -0.5
hypertension (High Blood Pressure 1.4 2.5 -0.79
Hypothyroidism 1.6 -1.6
Hypoxia 0.6 0.6
IgA nephropathy (IgAN) 1.9 -1.9
Inflammatory Bowel Disease 2.4 6.4 -1.67
Insomnia 0.8 0.2 3
Intelligence 0.5 1 -1
Intracranial aneurysms 0.7 0.5 0.4
Irritable Bowel Syndrome 1.6 1.1 0.45
Liver Cirrhosis 2.6 1.5 0.73
Long COVID 5.6 6.1 -0.09
Low bone mineral density 0.5 -0.5
Lung Cancer 1.4 -1.4
ME/CFS with IBS 0.1 2.6 -25
ME/CFS without IBS 1.9 0.8 1.37
Menopause 0.5 0.5
Metabolic Syndrome 4.9 4.2 0.17
Mood Disorders 6.2 7.5 -0.21
multiple chemical sensitivity [MCS] 0.8 0.5 0.6
Multiple Sclerosis 4.9 2.4 1.04
Multiple system atrophy (MSA) 1.5 0.6 1.5
Neuropathy (all types) 1 1
neuropsychiatric disorders (PANDAS, PANS) 0.2 0.2
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic 2.3 4.7 -1.04
NonCeliac Gluten Sensitivity 0.1 -0.1
Obesity 4.8 4 0.2
obsessive-compulsive disorder 2.4 4.5 -0.88
Osteoarthritis 0.9 0.9
Osteoporosis 0.6 1.4 -1.33
pancreatic cancer 0.3 0.3
Parkinson's Disease 3 2.1 0.43
Polycystic ovary syndrome 0.7 0.7 0
Postural orthostatic tachycardia syndrome 0.6 -0.6
Premenstrual dysphoric disorder 1.1 0 0
primary biliary cholangitis 0.2 0.5 -1.5
Psoriasis 2.6 2.5 0.04
rheumatoid arthritis (RA),Spondyloarthritis (SpA) 6.1 2.2 1.77
Rosacea 0.5 0 0
Schizophrenia 3.3 1.2 1.75
scoliosis 0.5 0.5
Sjögren syndrome 1.9 1.6 0.19
Sleep Apnea 1.5 1.7 -0.13
Small Intestinal Bacterial Overgrowth (SIBO) 0.5 0.4 0.25
Stress / posttraumatic stress disorder 1.3 3.1 -1.38
Systemic Lupus Erythematosus 2.7 0.8 2.38
Tic Disorder 0.2 1.9 -8.5
Tourette syndrome 0.4 0.2 1
Type 1 Diabetes 1.2 0.3 3
Type 2 Diabetes 4.9 4 0.23
Ulcerative colitis 1.1 3.2 -1.91
Unhealthy Ageing 4.2 2.2 0.91

This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.

Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.

Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β€―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.

Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.